Please assess the completion status of the following clinical trial:

Trial Title: Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed hepatocellular carcinoma or liver tumor responding to the Barcelona criteria~* Child-Pugh score of 5-6 (Class A)~* Tumor suitable for transarterial chemoembolization (one or more planned courses allowed)~* Tumor not suitable for surgical resection~* No extrahepatic metastases, including cerebral metastases~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Absolute neutrophil count ≥ 1.5 x 10\^9/L~* Platelet count ≥ 100 x 10\^9/L~* Hemoglobin ≥ 10 g/dL~* PT ≥ 50%~* Creatinine ≤ 120 μmol/L~* Bilirubin normal~* ALT/AST ≤ 3.5 times upper limit of normal (ULN)~* Alkaline phosphatases ≤ 4 times ULN~* Fibrinogen ≥ 1.5 g/L~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No portal vein thrombosis~* Able to comply with scheduled follow-up and management of toxicity~* No uncontrolled hypertension or requiring ≥ 2 classes of antihypertensive drugs~* No concomitant disease or uncontrolled severe disease~* No contraindications to the vascular occlusion procedure~* No prior or concurrent malignancy within the past 5 years, except adequately treated cone-biopsied carcinoma in situ of the cervix or basal cell carcinoma of the skin~* No psychiatric disability or social, family, or geographic reason for which the patient may not be followed regularly~PRIOR CONCURRENT THERAPY:~* At least 7 days since prior CYP3A4 inhibitors or inducers~* At least 3 months since prior radiofrequency ablation~* No prior chemotherapy~* No prior sunitinib, sorafenib, or any other inhibitors of angiogenesis~* No concurrent participation in another trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo 3cps/days 4 weeks over 6 during 1 year
- Sunitinib (Type: EXPERIMENTAL): sunitinib (SUTENT®) 37,5 mg/d (3 cps of 12,5 mg) orally 4 weeks over 6 (4 weeks of treatment followed by 2 weeks without treatment) during 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).